- Home
- TII vs ARCT Comparison
TII vs ARCT Comparison
Compare TII & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | ARCT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.5M | 163.4M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TII | ARCT |
|---|---|---|
| Price | $2.86 | $13.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $6.38 | ★ $24.11 |
| AVG Volume (30 Days) | 272.3K | ★ 952.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | $12.77 |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.81 | $5.50 |
| 52 Week High | $5.65 | $24.14 |
Technical Indicators
Market Signals| Indicator | TII | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 50.49 |
| Support Level | $2.75 | $13.12 |
| Resistance Level | $3.14 | $17.85 |
| Average True Range (ATR) | 0.18 | 1.28 |
| MACD | -0.03 | -0.50 |
| Stochastic Oscillator | 19.85 | 15.91 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.